Forced expression of the leukemia-associated gene EVI1 in ES cells: A model for myeloid leukemia with 3q26 rearrangements

Leukemia

Volumn 13, Issue 11, 1999, Pages 1639-1645

  Sitailo, S ^a   Sood, R ^a   Barton, K ^a   Nucifora, G ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; CANCER GENETICS; CELL DIFFERENTIATION; CELL GROWTH; CHROMOSOME 3Q; CONTROLLED STUDY; EDITORIAL; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; MEGAKARYOPOIESIS; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

EID: 0032723317     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401585     Document Type: Editorial

References (43)

1. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059-1064.
2. Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia 1997; 11: 2022-2031.
3. Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocation in acute and chronic myeloid leukemia. Blood 1995; 86: 1-14.
4. Morishita K, Paraganas E, Willman CL, Wittaker MH, Drabkin H, Oval J, Taetle R, Valentine MB, Ihle JN. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocation spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 1992; 89: 3937-3941.
5. Fonatsch C, Gudat H, Lengfelder E, Wandt H, Silling-Engelhardt G, Ludwig WD, Thiel E, Freund M, Bodenstein H, Schwieder G, Gruneisen A, Aul C, Schnittger S, Rieder H, Haase D, Hild F. Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26). Leukemia 1994; 8: 1318-1326.
6. Suzukawa K, Paraganas E, Gajjar A, Abe T, Takahashi S, Tani K, Asano S, Asou H, Kamada N, Yokota J, Morishita K, Ihle JN. Identification of a breakpoint cluster region 3′ of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 1994; 84: 2681-2688.
7. Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol 1995; 91: 490-501.
8. Peters P, Wlodarska I, Baens M, Criel A, Sellesdag D, Hagemeijer A, Van der Berghe H, Marynen P. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res 1997; 57: 564-569.
9. Raynaud S, Baens M, Grosgeorge J, Rodgers K, Reid C, Dainton M, Fuzibet J, Gratecos N, Taillan B, Ayraud N, Marynen P. Florescence in situ hybridization analysis of t(3;12)(q26;p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Blood 1996; 88: 682-689.
10. Nucifora G, Begy CR, Kubayashi H, Claxton D, Pedersen-Bjergaard J, Paraganas E, Ihle J, Rowley JD. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26:q22) translocations. Proc Natl Acad Sci USA 1994; 91: 4004-4008.
11. Morishita K, Parker DS, Mucenski ML, Copeland NG, Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988; 54: 831-840.
12. Morishita K, Paraganas E, Douglass EC, Ihle JN. Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of the cDNAs and structure of alternatively spliced transcripts. Oncogene 1990; 5: 963-971.
13. Pintado T, Ferro M, SanRoman C, Mayayo M, Larana J. Clinical correlations of the 3q21 3q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 1885; 55: 535-541.
14. Jenkins RB, Tefferi A, Solberg LA Jr, Dewald GW. Acute leukemia with abnormal thrombopoiesis and inversion of chromosome 3. Cancer Genet Cytogenet 1989; 39: 167-179.
15. Jotterand Bellomo M, Parlier V, Muhlematter D, Grob J, Beris P. Three new cases of chromosome 3 rearrangements in bands q21 and q26 with abnormal thrombopoiesis being further evidence to the existence of a 3q21 3q26 syndrome. Cancer Genet Cytogenet 1992; 59: 138-142.
16. Bouscary D, Fontenay-Roupie M, Chretien S, Hardy AC, Viguie F, Picard F, Melle J, Dreyfus F. Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndrome. Br J Haematol 1995; 91: 425-427.
17. Dreyfus F, Bouscary D, Melle J, Ribrag V, Guesnu M, Varet B. Expression of the EVI1 gene in myelodysplastic syndromes. Leukemia 1995; 9: 203-205.
18. Matsugi T, Morishita K, Ihle JN. Identification, nuclear localization, and DNA-binding activity of the zinc finger protein encoded by the Evi-1 myeloid transforming gene. Mol Cell Biol 1990; 10: 1259-1264.
19. Perkins AS, Fishel R, Jenkins NA, Copeland NG. Evi-1, a murine zinc finger proto-oncogene, encodes a sequence specific DNA-binding protein. Mol Cell Biol 1991; 11: 2665-2674.
20. Delwel R, Funabiki T, Kreider BL, Morishita K, Ihle JN. Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence specific binding to GA(C/T) AAGA(T/C)AAGATAA. Mol Cell Biol 1993; 13: 4291-4300.
21. Perkins AS, Kim JH. Zinc fingers 1-7 of EVI1 fail to bind to the GATA motif by itself but require the core site GACAAGATA for binding. J Biol Chem 1996; 271: 1104-1110.
22. Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA 1996; 93: 1642-1647.
23. Huang S, Shao G, Liu L. The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression. J Biol Chem 1998; 273: 15933-15939.
24. Nucifora G, Birn D, Espinosa R, Erickson P, LeBeau MM, Roulston D, McKeithan T, Drabkin H, Rowley JD. Involvement of the AMI1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood 1993; 81: 2728-2734.
25. Soderholm J, Kobayashi H, Mathieu C, Rowley J, Nucifora G. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia 1997; 11: 352-358.
26. Sood R, Talwar Trikha A, Chakrabarti SR, Nucifora G. MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-β1. Leukemia 1999; 13: 348-357.
27. McMahon AP, Bradley A. The Wnt-1 (int-1) proto-oncogene is required for the development of a large region in the mouse brain. Cell 1990; 62: 1073-1085.
28. Keller G, Kennedy M, Papayannopoulou T, Wiles M. Hematopoietic commitment during embryonic stem cell differentiation in culture. Mol Cell Biol 1993; 13: 473-486.
29. Wimmer K, Vinatzer U, Zwirn P, Fonatsch C, Wieser R. Comparative expression analysis of the antagonistic transcription factors EVI1 and MDS1-EVI1 in murine tissues and during in vitro hematopoietic differentiation. Biochem Biophys Res Comm 1998; 252: 691-696.
30. Brown J, Greaves M, Molgaard H. The gene encoding the stem cell antigen CD34 is conserved in mouse and expressed in hematopoietic progenitor cells. Int Immunol 1991; 3: 175-182.
31. Weiss M, Keller G, Orkin S. Novel insights into erythroid development revealed through in vitro differentiation of GATA1 -/-embryonic stem cells. Genes Dev 1994; 8: 1184-1192.
32. Olson M, Scott E, Hack A, Su G, Tenen D, Singh H, Simon M. Pu.1 is not essential for early myeloid gene expression but is required for terminal myeloid differentiation. Immunity 1995; 3: 703-710.
33. McClanahan T, Dalrymple S, Barkett M, Lee F. Hematopoietic growth receptor genes as marker of lineage commitment during in vitro development of hematopoietic cells. Blood 1993; 21: 2903-2909.
34. Montgomery L, Dallmann M. Analysis of cytokine gene expression during fetal thymic ontogeny using the polymerase chain reaction. J Immunol 1991; 147: 554-559.
35. Burstein S, Boyd C, Dale G. Quantitation of megakaryocytopoiesis in liquid culture by enzymatic determination of acetylcholinesterase. J Cell Physiol 1985; 122: 159-165.
36. Mucenski ML, Taylor BA, Copeland NG, Jenkins NA. chromosomal location of Evi1 in the DNA of AKXD murine myeloid tumors. Oncol Res 1988; 2: 219-233.
37. Mucenski ML, Taylor BA, Ihle JN, Hartley JW, Morse III HC, Jenkins NA, Copeland NG. Identification of a common ecotropic viral integration site, Evi1 in the DNA of AKXK murine myeloid tumors. Mol Cell Biol 1988; 8: 301-308.
38. Lemarchandel V, Ghysdael J, Mignotte V, Rahuel C, Romeo PH. GATA and Ets cis-acting sequences mediate megakaryocytespecific expression. Mol Cell Biol 1993; 13: 668-676.
39. Bastian LS, Yagi M, Chan C, Roth GJ. Analysis of the megakaryocyte glycoprotein IX promoter identifies positive and negative regulatory domains and functional GATA and Ets sites. J Biol Chem 1996; 271: 18554-18560.
40. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 1997; 16: 3965-3973.
41. Vyas P, Atul K, Jackson CW, Orkin SH. Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 1999; 93: 2867-2875.
42. Tsang AP, Fujiwara V, Hom DB, Orkin SH. Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcription cofactor FOG. Genes Dev 1998; 12: 1176-1188.
43. Kreider B, Orkin S, Ihle J. Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the EVI1 myeloid-transforming gene. Proc Natl Acad Sci USA 1993; 90: 6454-6458.